NHI to reimburse Zeffix for liver sclerosis and hepatitis

Published: 2005-09-08 07:00:00

Updated: 2005-09-08 07:00:00

The NHI reimbursement of Zeffix (lamivudine) and Hepsera (adefovir) will be granted for the chronic B hepatitis patients accompanied with hepatitis and liver sclerosis for maximum 2 years when showing the e-antigen and HBV-DNA test every 3 month.

GSK said on Sept. 5 that the patients with liver diseases accompanied with liver sclerosis could get the additional NHI reimbursement benefits for ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.